Join the Department of Economics for a critical discussion of the effects of using prescription drugs off-label.
Speaker: Katharina Blankart, Bern University of Applied Sciences.
Abstract
Does using prescription drugs off-label increase disability and medical expenditure?
This paper uses a unique dataset to evaluate off-label vs. on-label drug use in the US non-institutionalized population.
Patients using drugs off-label have on average $515 higher medical expenditure and work-loss cost. Pharmaceutical innovation has direct and indirect effects on off-label drug use.
Market size is indicative of the fraction of treatments used off-label. Their findings have implications for regulation and welfare.
They will address endogeneity issues by demonstrating that patients with higher disease severity do not experience higher off-label uses and by controlling for unobserved individual and condition effects.
About the speaker
Katharina is a business economist with interests in health economics, policy and health care management.
She is currently leading the team of health economics and policy at the School of Health Professions at the Bern University of Applied Sciences in Bern, Switzerland.
Her research is in the areas of health and innovation.
She studies the institutional settings that determine value of and access to health technology, including how providers and patients use technology to improve health and health care.
She is especially interested in the economics and management of pharmaceutical care.
Attendance at City events is subject to our terms and conditions.